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often seen in effectively communicating this to treatment prac-
tices within the clinical community to the Primary Care Trust
(PCT) level. Such delays can result in the continued prescribing of
less cost-effective drugs. We, therefore, looked at several poten-
tial approaches to enhance communications through improved
user interface capabilities of existing Excel-based models. Three
approaches were considered, all utilising existing Windows-
based tools and programming languages: HTML, Visual Basic,
or HTML/Visual Basic (hybrid). RESULTS: We successfully
developed a two-step methodology, based on a HTML/
VisualBasic approach, which can be used to quickly develop
sophisticated graphical user interfaces directly within the struc-
ture of an existing economic model. The advantage of this novel
approach is that there is no longer a need to rely on full replica-
tions of models in a separate programming language (such as
shockwave), which carries consistency issues, or the limited basic
spreadsheet interface. Also, the approach can be applied itera-
tively during model design for submission to a regulatory body,
which is a more efﬁcient development process. CONCLUSIONS:
A new method of presenting pharmacoeconomic results has been
developed, which can be designed within existing Excel-based
economic models, providing an enhanced, user-friendly, interac-
tive tool which can replicate real-world prescribing patterns for a
given scenario. These tools can greatly improve communications
of economic and clinical messages to PCTs.
CONCEPTUAL PAPERS & RESEARCH ON
METHODS—Cost Methods
PMC4
FEASIBILITY OF CONDUCTING BUDGET IMPACT ANALYSIS
INTHE SOCIAL SECURITY INSTITUTION OFTURKEY
Calgan Z1, Ozer A2,Yegenoglu S1
1Hacettepe University, Ankara,Turkey, 2Social Security Institution,
Ankara,Turkey
OBJECTIVES: To determine whether the Social Security Institu-
tion of Turkey has an appropriate system to collect and process
data in order to conduct budget impact analysis. METHODS:
A literature review was conducted in order to specify the data
needed for budget impact studies. Then, interviews with the
personnel of the Monitoring and Evaluation Department and
Pharmaceuticals and Pharmacy Department in the Social Security
Institution were made. Besides, the literature concerning General
Health Insurance MEDULA system was reviewed. Data was
assessed in terms of its existence and accessibility. RESULTS:
After using Web Electronic Bill System (w-ELF) in 2006,
MEDULA was established in order to transfer data between
health care settings and general health insurance system in 2007
in Turkey. Currently, patient characteristics such as age and
gender, information regarding diagnosis, examination, consulta-
tion, analysis, operation, complications and pharmaceuticals and
medical supplies used can be recorded via MEDULA. However,
patients and number of patients who have a speciﬁc health con-
dition or who use a certain pharmaceutical product cannot be
determined via web services of the system. Similarly, costs paid
for a speciﬁc medical treatment cannot be identiﬁed via
MEDULA. On the other hand, it is indicated that there is a
project to determine number of patients who have a speciﬁc
health condition through the system. CONCLUSIONS:
Although there is relevant raw data, number of eligible people
with a speciﬁc indication, extent of implementation of a phar-
maceutical and incremental cost per patient which are necessary
for budget impact studies cannot be accessed through the existent
system in the Social Security Institution of Turkey. Thus, some
improvement in data processing is needed.
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OBJECTIVES: To determine a rule or the threshold beyond
which missing data affects utility estimates, thus requiring resort
to imputation techniques. This analysis examined UK data and is
based on patient and payers’ perspectives. This paper moves
beyond the now established consensus against listwise and pair-
wise deletion of missing data toward comparably simple methods
of analysis that achieve greater accuracy. METHODS: EuroQoL
EQ-5D measurements of health utility obtained by survey of
secondary care patients after hospitalisation were examined in
order to develop missing data thresholds beyond which overall
data quality would be compromised and thus imputation tech-
niques required. Using gender, index age, length of stay in hos-
pital, number of comorbidities, and cost of care, patients were
stratiﬁed according to a primary diagnoses of 5 major chronic
conditions, in terms of cost. Each dataset, consisting of between
150 and 450 patients, was randomly assigned missing values,
based on two broad classes of randomness in the literature:
missing at random data and not missing at random data. Not
missing at random data was deﬁned as data containing paired
variables with correlation coefﬁcients of great than 0.50. Com-
parisons among primary ICD-10 diagnoses set at 5%, 10%,
15%, and 20% were examined. The missing data threshold for
each diagnosis was then calculated by model simulation using
various degrees of missing data. RESULTS: For cardiovascular
diseases, the missing data threshold was between 8.5% and 12%.
Rates of missingness beyond these levels tended to decrease the
accuracy of utility measures when compared with the full base-
line dataset. For diabetes, chronic pulmonary disease, and mus-
cular skeletal disorders, the range was lower. Therefore, for a
given cost of care, cost-utility ratios decline due to the increase in
uncertainty of the estimates. CONCLUSIONS: Descriptive mea-
sures of health status are affected by diagnosis and other factors.
The development of a rule that enables researchers to determine
whether missing data is likely to have a material effect on the
measurement of health status can lead to improved research
quality and, in turn, better allocation of health care resources.
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OBJECTIVES: To provide a ready-to-use framework for com-
puting the social discount rate, the proper rate for discounting of
social programmes, including health care programmes, given the
inoptimality of market mechanisms to derive the optimal dis-
count rate. METHODS: A social time preference methodology
derived from Feldstein work (“The derivation of social time
preference rates”, Kyklos 18, 1965) is applied to calculate social
discount rates as social time preference (STP) rates across 167
countries for a speciﬁc year (2006) and across time from 2005–
2050 for a country case (Brazil). STR rate derived is deﬁned as
dt = (1 + pt)1-a(1 + gt)s(1 + r) - 1, where a is the population
weight, p the population growth, g the per-capita income growth,
s the coeffcient of risk aversion and r the pure time preference
rate. Data were obtained in the literature and databases (World
Development Indicators (World Bank, 2007), World Economic
Outlook (IMF, 2007) and IBGE (Instituto Brasileiro de Geograﬁa
A560 Abstracts
e Estatística)). RESULTS: Our computed values vary across
countries and across time. The average STP rate for the 167
countries in the sample is 6.8% and the standard deviation 3.9%.
The ﬁgures ranged from -6.8% for Equatorial Guinea to 18.6%
for Armenia. For Brazil, STP rates display a decreasing proﬁle
across time, with an average rate of 4.7%. Computed ﬁgures
vary from 3.6% to 5.5%. CONCLUSIONS: The standardisation
of the use and estimation of discount rates in the economic
evaluation of health care programmes (EEHCP) is a core quest,
especially with the increase of EEHCP as a tool for decision
making. The variation of STR rate results indicate the need for
country-speciﬁc discount rate estimation.
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OBJECTIVES: This study aims to compare the impact of two
different sources of resource use, self-report versus routine
registrations, on incremental cost-effectiveness ratios (ICERs).
METHODS: Data were obtained from a cost-effectiveness study
performed alongside a two-year randomized controlled trial
evaluating the effect of an INTERdisciplinary COMmunity-
based management program (INTERCOM) for patients with
chronic obstructive pulmonary disease (COPD). The program
consisted of exercise training, nutritional therapy, education and
smoking cessation support offered by community-based physio-
therapists and dieticians and hospital-based respiratory nurses.
Data on caregiver visits, hospitalizations, diet nutrition, devices,
(un)paid help, travel expenses and time lost from paid work over
the two-year period were collected using a cost booklet. In addi-
tion, data on hospital admissions and outpatient visits, visits to
the physiotherapist, dietician or respiratory nurse, diet nutrition
and outpatient medication were obtained from hospital- and
billing records and local pharmacies. The cost per QALY was
calculated in two ways, using data from the cost booklet or
registrations. RESULTS: In total 175 patients were included in
the study. Agreement between self-report and registrations was
good for hospitalizations (r = 0.96), diet nutrition (r = 0.91) and
physiotherapist visits (r = 0.89), but above 0.58 for all other
types of care. The total cost difference between the registrations
and the cost booklet was €464 with the highest difference for
hospitalizations 386 euro. Based on the cost booklet the cost
difference between the treatment group and usual care was
€2,444 (95% CI: -819–5,950), which resulted in an ICER of
€29,100/QALY. For the registrations, the results were €2,498
(95% CI: -88–6,084) and €29,390/QALY, respectively. No dif-
ferences were found in the cost-effectiveness planes and the
acceptability curves between the two methods. CONCLUSIONS:
This study showed that the use of self-reported data or data from
routine registrations effected within group costs, but not between
group costs or the ICERs.
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OBJECTIVES: To assess trends in the prevalence and type of
economic analysis alongside randomized controlled trials (piggy-
back trials) published between 1997 and 2007. METHODS: We
searched Medline for a total number of Randomized Controlled
Trials published between 1997 and 2007. Economic studies
alongside RCTs were searched by using the additional MeSH
terms, costs and cost analysis. The abstract of each retrieved,
English-language study was reviewed and economic studies
alongside RCTs were identiﬁed. Included studies were catego-
rized further by the type of analysis, perspective and interven-
tions. RESULTS: Our search identiﬁed a total of 131,454 RCTs
and 2820 economic analysis alongside RCTs. A total of 2077
studies met inclusion criteria and further analyzed. Only 1.58%
of published RCTs included economic analysis. The prevalence
of economic studies alongside RCTs as a proportion of RCTs was
fairly constant over 1997–2007, except for the year 2000 where
a higher prevalence (2.07%) was observed. Cost effectiveness
analyses was most frequently reported (46.12%) followed by
cost minimization (2.74%), cost beneﬁt (2.6%) and cost utility
(1.4%). More than one type of analyses was reported in 3.17%
of studies. The remaining 44.05 % of studies were either cost
analysis or cost-consequence analysis or were unclear. The inter-
ventions considered in the trials were drugs (36.3%), devices or
surgical techniques (22.14%), behavioral studies (4.91%), pre-
ventive studies (3.9%), and others (30.38%).The perspective of
economic analysis was stated in only 8.32% of studies. Federal,
hospital, patient, payer, societal and state agency perspective
were reported by 1.2%, 1.3%, 0.38%, 1.05%, 2.84%, and
0.52% of studies respectively. CONCLUSIONS: We observed an
increase in the prevalence of economic analysis in randomized
controlled trials than earlier years. Also, the number of drug
trials and devices and surgical technique trials has increased from
before 1997. The reporting of trial perspective was found very
low. This could be because of external-validity problems with
piggy-back trials.”
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OBJECTIVES: Economic evaluation of health technologies is
increasingly used to inform decision-making in health policy. It is
standard practice in cost-effectiveness analysis to discount future
health beneﬁts at the same rate as costs and to apply a baseline
rate between three and ﬁve percent a year. Public health advo-
cates of prevention programmes often argue that devaluing
future health gains through discounting is inappropriate. The
purpose of this paper is to re-examine the arguments of the social
time preference approach for discounting health beneﬁts at some
positive rate and at the same rate as the costs. METHODS: The
paper is based on a systematic review of the literature on the
foundations of discounting in the economic evaluation of health
care programmes published during the time period 1989–2008.
RESULTS: According to the social time preference approach the
main arguments for discounting are the individual’s uncertainty
about the returns of investment, diminishing marginal utility and
pure time preference. None of these arguments convincingly
supports a positive and distinct discount rate for health gains.
Particularly the argument of pure time preference is challenged,
e.g. by the problem of myopia, the divergence between private
and collective decision behaviour, and the neglect of distribu-
tional concerns of public health policy. A more fundamental
weakness of the welfaristic framework is that is does not provide
an appropriate conceptual basis for dealing with the question
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